Alzamend Neuro Inc
ALZN
NASDAQ
Biotechnology
$1.55
USD
+0.09 (+6.16%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.00M
Volume 86.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-8.77M
TTM
-94.3%
YoY
Operating Cash Flow
$-8.07M
TTM
-22.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.7 | 1.0 | 0.8 | 0.9 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.1 | 2.7 | 1.0 | 2.2 | 2.9 |
Operating Income | -1.1 | -2.7 | -1.0 | -2.2 | -2.9 |
EBITDA | -1.1 | -2.7 | -1.0 | -2.2 | -2.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.0 | 0.0 |
Income Before Income Taxes | -1.1 | -2.7 | -1.0 | -2.2 | -2.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.1 | -2.7 | -1.0 | -2.2 | -2.9 |
Consolidated Net Income / Loss | -1.1 | -2.7 | -1.0 | -2.2 | -2.9 |
Net Income Attributable to Common Shareholders | -1.6 | -2.7 | -1.0 | -2.2 | -2.9 |
Basic EPS | -$2.30 | -$1.28 | -$0.30 | -$0.58 | -$0.71 |
Diluted EPS | -$2.30 | -$1.28 | -$0.30 | -$0.58 | -$0.71 |
Basic Shares Outstanding | 0.7M | 2.1M | 3.4M | 3.8M | 4.1M |
Diluted Shares Outstanding | 0.7M | 2.1M | 3.4M | 3.8M | 4.1M |